Biocon Biologics' drug substance facility in Bengaluru has been classified by the USFDA as voluntary action indicated after a cGMP inspection conducted in February 2024. The classification means that while some objections were noted, no regulatory action is recommended. The facility is responsible for supplying rh-Insulin drug substance to the US.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.